Biogen

Focke Ziemssen, Michelle Sylvanowicz, Winfried M. Amoaku, Tariq Aslam, Bora Eldem, Robert P. Finger, Richard P. Gale, Laurent Kodjikian, Jean-François Korobelnik, Xiaofeng Lin, Anat Loewenstein, Paul Mitchell, Moira Murphy, David R. Owens, Nick Parker, Ian Pearce, Francisco J. Rodríguez, Jude Stern, S. James Talks, David T. Wong, Tien Yin Wong, and Jane Barratt disclose various financial interests including travel grants, personal fees, advisory board memberships, speaker fees, research sponsorship, and consulting roles with companies such as Allergan, AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Janssen, Novartis, Novo Nordisk, Merck, Regeneron, Roche, Sanofi, and others.

John Miller cares for his wife Cheryl, who has Alzheimer's, navigating clinical trials and treatment setbacks. Despite challenges, John remains hopeful for future treatments and continues to seek options for Cheryl, emphasizing the emotional toll and daily struggles faced by caregivers.

The Precision Medicine market is projected to grow from $89.9B in 2023 to $161.1B by 2030, driven by tech advancements, declining genomic sequencing costs, and personalized treatments. Oncology, chronic diseases, and AI integration are key growth areas.

Ionis Pharmaceuticals awaits FDA decision on olezarsen by Dec. 19, a therapy for familial chylomicronemia syndrome with potential for broader use. CEO Brett Monia shifted strategy to develop drugs independently, aiming to maximize value for both company and patients.

The inMIND trial showed Monjuvi + Rituxan + Revlimid improved progression-free survival (PFS) to 22.4 months vs. 13.9 months for placebo in R/R follicular lymphoma. Key secondary endpoints also favored the experimental arm. Monjuvi aims to become a new standard-of-care option, with potential competition from other therapies.

BenevolentAI co-founder Kenneth Mulvaney announces restructuring to return to 'techbio' roots, including layoffs and delisting from Euronext Amsterdam. Tasca Therapeutics raises $52M in Series A funding for cancer drug development. Eli Lilly's board approves $15B stock buyback and 15% dividend increase. AbbVie's Parkinson's drug tavapadon succeeds in Phase 3 trial, prompting approval filing plans. Biogen appoints Tim Power as head of investor relations.

Seth Lederman, co-founder, CEO & Chairman of Tonix Pharmaceuticals, is a physician, scientist, and entrepreneur with extensive experience in molecular immunology and autoimmune diseases. Steve Gardner, CEO of Precision Life, has over 30 years of experience in precision medicine, drug discovery, and computational biology, and is involved in genomics and AI-enabled drug discovery.

Dr. Horan, Dr. Sauder, Dr. Ramsay, and Dr. Yohn are Bristol Myers Squibb employees. Dr. Harvey has affiliations with multiple companies, including Bristol Myers Squibb. Dr. Ramsay holds Bristol Myers Squibb stock. Dr. Keefe consults for various companies and has received royalties. Dr. Davis consults for several companies. Dr. Paul has roles at Karuna Therapeutics, Sage Therapeutics, and Voyager Therapeutics. Dr. Brannan was with Karuna Therapeutics and now consults for Bristol Myers Squibb.